Background illustration for clinical trials search

Paid Clinical Trials Nashville

Discover 1,248 paid clinical trials in Nashville, Tennessee. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 1,248

A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

for

Renal Cell Carcinoma

Location: Nashville TN, Philadelphia PA, New York NY,

Sponsor: Bristol-Myers Squibb

Sex: All

Age: 18+

Code: NCT07195682

Phase1, Recruiting

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

for

Large B-cell Lymphoma, Lymphoma, B-Cell,

Location: Nashville TN, Louisville KY, Atlanta GA, Cincinnati OH,

Sponsor: Lyell Immunopharma, Inc.

Sex: All

Age: 18+

Code: NCT07188558

Phase3, Recruiting

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

for

Pancreatic Cancer, PDAC,

Location: Nashville TN, Atlanta GA, Indianapolis IN, Maumee OH,

Sponsor: Revolution Medicines, Inc.

Sex: All

Age: 18+

Code: NCT07252232

Phase3, Recruiting

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

for

Metastatic Castration-resistant Prostate Cancer

Location: Nashville TN, Louisville KY, Newnan GA, Cincinnati OH,

Sponsor: Amgen

Sex: Male

Age: 18+

Code: NCT07213674

Phase3, Recruiting

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

for

Bladder Cancer, Squamous Cell Carcinoma of the Lung,

Location: Nashville TN, Atlanta GA, Cleveland OH, Grand Rapids MI,

Sponsor: EvolveImmune United, Inc

Sex: All

Age: 18+

Code: NCT07217171

Phase1, Recruiting

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

for

Advanced/Metastatic Solid Tumors, Bladder Cancer,

Location: Nashville TN, Toronto, Conroe TX, League City TX,

Sponsor: Pfizer

Sex: All

Age: 18+

Code: NCT07090499

Phase1, Recruiting

Gene Therapy for HER-Positive Cancer (SENTRY-HER2)

for

HER2 Expressing Solid Tumors

Location: Nashville TN, Cleveland OH, Jacksonville FL,

Sponsor: Vironexis Biotherapeutics Inc.

Sex: All

Age: 18+

Code: NCT07192432

Phase1, Phase2, Recruiting

A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

for

Follicular Lymphoma

Location: Nashville TN, Lexington KY, Durham NC, Duarte CA

Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT07634471

Phase2, Phase3, Recruiting

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

for

Prostate Cancer Metastatic

Location: Nashville TN, St Louis MO, Hattiesburg MS, Roanoke VA,

Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06136624

Phase3, Recruiting

Neoadjuvant Darovasertib in Primary Uveal Melanoma

for

Uveal Melanoma

Location: Nashville TN, Grand Rapids MI, Jacksonville FL,

Sponsor: IDEAYA Biosciences

Sex: All

Age: 18+

Code: NCT07015190

Phase3, Recruiting

Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

for

Urothelial Cancer, Urinary Bladder Neoplasms

Location: Nashville TN, Fort Wayne IN, Columbia MO, Niles IL,

Sponsor: Astellas Pharma Global Development, Inc.

Sex: All

Age: 18+

Code: NCT07566156

Phase3, Recruiting

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

for

Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM)

Location: Nashville TN, Birmingham AL, Columbus OH,

Sponsor: SCRI Development Innovations, LLC

Sex: All

Age: 19+

Code: NCT06974786

Phase2, Recruiting

A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

for

Esophageal Squamous Cell Carcinoma

Location: Nashville TN, Memphis TN, Kansas City MO, Detroit MI,

Sponsor: Daiichi Sankyo

Sex: All

Age: 18+

Code: NCT06644781

Phase3, Recruiting

TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

for

Lymphoma, Lymphoma, Non Hodgkin

Location: Nashville TN, St Louis MO, Grand Rapids MI, Houston TX,

Sponsor: Treeline Biosciences, Inc.

Sex: All

Age: 18+

Code: NCT07082803

Phase1, Recruiting

A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)

for

Colon Cancer, Rectal Cancer, Colorectal Cancer,

Location: Nashville TN, Columbia MO, Salem VA,

Sponsor: SCRI Development Innovations, LLC

Sex: All

Age: 18+

Code: NCT07011576

Phase2, Recruiting

Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors

for

Locally Advanced/Metastatic Solid Tumors

Location: Nashville TN, Denver CO, Indianapolis IN, Houston TX,

Sponsor: InSilico Medicine Hong Kong Limited

Sex: All

Age: 18+

Code: NCT06414460

Phase1, Phase2, Recruiting

A Study of ZL-1310 in Participants With Selected Solid Tumors

for

Solid Tumors

Location: Nashville TN, Peoria IL, Cleveland OH, Detroit MI,

Sponsor: Zai Lab (Shanghai) Co., Ltd.

Sex: All

Age: 18+

Code: NCT06885281

Phase1, Phase2, Recruiting

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

for

Lymphoma, Large B-Cell, Diffuse

Location: Nashville TN, Elizabethtown KY, Knoxville TN,

Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06890884

Phase2, Recruiting

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

for

Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer,

Location: Nashville TN, St Louis MO, Ann Arbor MI,

Sponsor: Verastem, Inc.

Sex: All

Age: 18+

Code: NCT07020221

Phase1, Phase2, Recruiting

Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors

for

Malignant Mesothelioma, Metastatic Malignant Solid Tumor,

Location: Nashville TN, Denver CO, Chicago IL, Cleveland OH,

Sponsor: InSilico Medicine Hong Kong Limited

Sex: All

Age: 18+

Code: NCT06566079

Phase1, Recruiting

Paid Clinical Trials Nashville

Filter results

A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

Interested in new trials?

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

Gene Therapy for HER-Positive Cancer (SENTRY-HER2)

A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

Neoadjuvant Darovasertib in Primary Uveal Melanoma

Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)

Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors

A Study of ZL-1310 in Participants With Selected Solid Tumors

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors